| Objective To investigate the correlation between Preptin and bone mineral density (BMD) in type 2 diabetes induced osteoporosis. Methods Eighty-eight patients with type 2 diabetes were included. They were divided into three groups according to T value of BMD: normal bone mass group (T-value greater than -1.0, N group), osteopenia group (T-value less than -1.0 and greater than -2.5, R group), and osteoporosis group (T-value less than -2.5, OP group). The general clinical data, clinical laboratory data, BMD, plasma leptin, connective tissue growth factor (CTGF), and bone specific alkaline phosphatase (BAP) levels among the three groups were compared. Pearson correlation analysis was used to study the correlation between BMD and general data, clinical laboratory data, and bone metabolism related indicators. SPSS 19.0 statistical software was used to draw the correlation curve between leptin, CTGF, and BAP. Results There were significant differences in weight and BMI among the three groups (P<0.05). There were significant differences in BMD and bone metabolism related indexes among the three groups. With the decrease of BMD, the levels of leptin, CTGF, and BAP among the three groups decreased gradually, with significant differences (P<0.05). BMD of L2-L4 was positively correlated with Preptin, ALP-B, and CTGF, and Preptin was positively correlated with ALP-B and CTGF (P<0.05). Conclusion Preptin plays an important role in the occurrence and development of type 2 diabetes induced osteoporosis by regulating the levels of CTGF and BAP. Preptin is expected to become a new target for the treatment of type 2 diabetes induced osteoporosis. |